ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
Myovant Sciences Ltd

Myovant Sciences Ltd (MYOV)

26.98
0.00
(0.00%)
마감 04 2월 6:00AM
26.98
0.00
( 0.00% )
시간외 단일가: 9:00AM

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

가격
26.98
매수가
-
매도가
-
거래량
-
0.00 일간 변동폭 0.00
0.00 52주 범위 0.00
전일 종가
26.98
개장가
-
최근 거래 시간
마지막 거래 시간
-
평균 볼륨(3m)
-
재정 규모
-
VWAP
-

MYOV 최신 뉴스

Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022

Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter...

MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences

MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences PR Newswire NEW YORK, Dec. 16, 2022 NEW YORK, Dec. 16, 2022...

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven...

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources

BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November...

Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022

On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and Myovant Sciences (Myovant) announced that they have...

Myovant Sciences Cancels Second Quarter Earnings Conference Call

BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September...

Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement

Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash Combination Provides Expertise and Resources to Address Unmet Patient Needs in Women’s Health and...

Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement

Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement PR Newswire NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 Sumitovant Biopharma to...

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven...

CORRECTION -- Myovant Sciences, Inc.

BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m." earlier...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

MYOV - Frequently Asked Questions (FAQ)

What is the current Myovant Sciences share price?
The current share price of Myovant Sciences is US$ 26.98
What is the 1 year trading range for Myovant Sciences share price?
Myovant Sciences has traded in the range of US$ 0.00 to US$ 0.00 during the past year

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
EVCEntravision Communications Corp
US$ 2.46
(13.89%)
1
LPLLG Display Co Ltd
US$ 3.49
(13.31%)
7
CIFMFS Intermediate High Income Fund
US$ 1.91
(9.77%)
5
GCTSWts each whole warrant exercisable one share of Common Stock
US$ 2.20
(8.91%)
926
CVEOCiveo Corporation New
US$ 25.12
(8.28%)
14
PSFEPaysafe Limited
US$ 17.29
(-10.55%)
8
MTALMAC Copper Limited
US$ 9.22
(-10.49%)
1
TPCTutor Perini Corporation
US$ 21.16
(-6.95%)
4
ENICEnel Chile SA
US$ 2.85
(-6.86%)
5
UTLUnitil Corp
US$ 51.09
(-5.67%)
5
NOKNokia Corp
US$ 4.67
(1.08%)
842.67k
QBTSD Wave Quantum Inc
US$ 5.90
(2.43%)
256.96k
NIONIO Inc
US$ 4.39
(2.57%)
241.24k
SESSES AI Corporation
US$ 1.19
(2.59%)
160.15k
XPEVXPeng Inc
US$ 16.79
(7.01%)
157.18k

MYOV Discussion

게시물 보기
Cosa Cosa 2 년 전
What a run from the $7's a few months back. Closed my entire position on Tuesday. Sitting on powder ready to go. ARDX looking really strong right now coming off its lows with some upcoming catalyst.
👍️0
MDizzle MDizzle 2 년 전
I was hoping for $5. more a share but a win is a win haha
👍️0
Cosa Cosa 2 년 전
Woohoo Cheers!!
👍️0
Cosa Cosa 2 년 전
Woohoo Cheers!!
👍️0
Cosa Cosa 2 년 전
Nice! patience always pays. Agree it will lose some steam quickly. Half my position is gone, will add if it goes back down below $13's. Hopefully it does get a bigger offer, but not waiting for that to happen.

Followed
👍️0
Cosa Cosa 2 년 전
Lol. No worries it will make a comeback. Even though management is quite, they need the share price up. They're options are worthless at this point. Just need to be patient. Good Luck!
👍️0
Dallas-Cowboys Dallas-Cowboys 2 년 전
I also took profits on most of the shares I owned I have been in this for quite awhile at $21.40 I always thought Pfizer would buy this but when I read Sumo said they would not sell their shares that changed my thinking. I didn’t make much for the amount of time I held but I was under water for along time wondering if I would just break even. If they don’t raise their bid this will crash
👍️0
rosemountbomber rosemountbomber 2 년 전
Yep taking profits here as don't want to be burned like with AUPH.
👍️0
Cosa Cosa 2 년 전
Taking more off the top. What a great day here!
👍️0
nferna nferna 2 년 전
The tell in that sad situation was the insider sales near the top. (Wish I had paid more attention to that, major lesson learned)
👍️0
Dallas-Cowboys Dallas-Cowboys 2 년 전
What we will see is if Pfizer wants to partner with Sumo or do they want the whole thing. If so they have to buy all the shares and Sumo will be in the drivers seat . Should become interesting
👍️0
Dallas-Cowboys Dallas-Cowboys 2 년 전
Sorry to hear that I don’t think this is the same situation. They low balled probably knowing it wouldn’t fly, there are 3 Sumo people on Myov board. They will sweeten the offer now how much who knows but we will see soon enough
👍️0
rosemountbomber rosemountbomber 2 년 전
I have tried to put all the details of that sordid story behind me, but basically last Fall, Bristol Meyers was set to buy Aurinia. Financial officer released the story and then quickly erased it and was later fired, but ultimately the CEO thought the deal was not good enough and things went south from there. Then of course sales of their very expensive drug have gone nowhere and stock cratered to 1/5 of supposed deal price.
👍️0
Dallas-Cowboys Dallas-Cowboys 2 년 전
Not aware of that what happened
👍️0
rosemountbomber rosemountbomber 2 년 전
Hope there is no screw up like Peter Greenleaf with Aurinia.
👍️0
Dallas-Cowboys Dallas-Cowboys 2 년 전
That would value around 2.3 billion no way too cheap they know it
👍️0
DewDiligence DewDiligence 2 년 전
Maybe. The problem (for MYOV minority shareholders) is that Sumitovant can play hardball and force the issue if they choose to do so.
👍️0
Dallas-Cowboys Dallas-Cowboys 2 년 전
It is just getting started first volley they already turned it down. They will be coming back higher and hopefully this will get Pfizer off the fence. Getting interesting
👍️0
DewDiligence DewDiligence 2 년 전
https://finance.yahoo.com/news/myovant-sciences-special-committee-board-233600693.html

I warned against exactly this kind of “takeunder” in #msg-167606619.
👍️0
Dallas-Cowboys Dallas-Cowboys 2 년 전
I believe they want to be taken over now they might not want a hostile takeover but why do we care if SP goes up
👍️0
Cosa Cosa 2 년 전
Either way they are going to make a killing. What a great position to be in. They keep adding shares too. As long as it is not a hostel takeover, that would be catastrophic for retail.
👍️0
Dallas-Cowboys Dallas-Cowboys 2 년 전
Yes Sumo owns 53% and has 3 board members so it will be their decision. So if Pfizer does want it at $40 to $50 a share that is a lot of cash for Sumo. Otherwise they will have to wait until myovant grows their revenue and turns profitable.
👍️0
Cosa Cosa 2 년 전
With Sumitomo owning the majority of shares it will be up to them if they want to sell or not.
👍️0
Dallas-Cowboys Dallas-Cowboys 2 년 전
With their share count at around 100 million approximately 5 billion buyout definitely in Pfizer’s wheelhouse
👍️0
rosemountbomber rosemountbomber 2 년 전
So you are looking for a BO at close to $50 per share?
👍️0
Dallas-Cowboys Dallas-Cowboys 2 년 전
Yes Sumo owns majority and some people think they will eventually buy the rest but I’m not in that camp. I think Pfizer will be the suitor. They are in the buying mode in that 5 billion range which myov will fall into imo
👍️0
Cosa Cosa 2 년 전
Sumitomo owns most of the shares, so there is hardly any shares for the public. Price can really move with little volume. The increasing revenue and recent nod from FDA also a factor. The partnership with PFE was a great idea, the long arms of BP can really move a product.
👍️0
Cosa Cosa 2 년 전
Took a little more off the table today. MYOV! $7 back in May, what a nice come back from yearly low.
👍️0
Dallas-Cowboys Dallas-Cowboys 2 년 전
Listened to the conference yesterday seemed run of the mill no questions or mention of buyout. Sure didn’t explain run any theories here?
👍️0
rosemountbomber rosemountbomber 2 년 전
Difficult to believe we wouldn't see 52 week highs. Another approval and sales climbing.
👍️0
Cosa Cosa 2 년 전
Nice break to the upside!
👍️0
Cosa Cosa 2 년 전
Consolidating the past few weeks. Which way is it going to break....
👍️0
Cosa Cosa 2 년 전
Took some profits today. Looking really bulllish!
👍️0
rosemountbomber rosemountbomber 2 년 전
Any guess as to what to expect in premarket Monday?

Glad I swung my AUPH money over here a couple of weeks ago adding to my position here I started in the Spring.
👍️0
Cosa Cosa 3 년 전
MYFEMBREE FDA Approved! Looking forward to Monday!
👍️0
Cosa Cosa 3 년 전
Those bargain prices from a few months back is up 70%!
👍️0
Cosa Cosa 3 년 전
Up and to the right.
👍️0
Cosa Cosa 3 년 전
If volume comes back this will blast off.
MYOV!
👍️0
Cosa Cosa 3 년 전
Go baby go!! MYOV! Going up on really low volume. Not sure if we can hold these gains.
👍️0
DewDiligence DewDiligence 3 년 전
The deal terms were not better than expected, so the sell-off is not especially surprising on a day like today.
👍️0
Cosa Cosa 3 년 전
Good news does nothing in fearful market. 7's...wow, trading like phase 2 company with no FDA approved drugs.
👍️0
Cosa Cosa 3 년 전
I'm holding bags for sure lol
👍️0
DewDiligence DewDiligence 3 년 전
MYOV bags European partner for Orgovyx:

https://www.globenewswire.com/news-release/2022/05/09/2438369/0/en/Myovant-Sciences-and-Accord-Healthcare-Ltd-Enter-into-Exclusive-License-Agreement-to-Commercialize-ORGOVYX-for-Advanced-Hormone-Sensitive-Prostate-Cancer-in-Europe.html Myovant Sciences and Accord Healthcare, Ltd. (Accord) today announced that they have entered into an exclusive license agreement for Accord to commercialize relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name ORGOVYX (relugolix, 120 mg) in the European Economic Area, United Kingdom, Switzerland and Turkey…

…Under the terms of the agreement, Myovant will receive an upfront payment of $50 million and is eligible to receive commercial launch, sales-based and other milestones totaling up to $90.5 million. In addition, Myovant is eligible to receive tiered royalties from the high-teens to mid-twenties on net sales.
👍️0
Cosa Cosa 3 년 전
Cheers Bro! buying the dip in both
👍️0
winepro1 winepro1 3 년 전
Cosa,
I see you are also into MYOV. I no longer post on AUPH as I am tired of BR, Cervelo, Whalatane, and Rosemount bomber, who I suspect are all questionable posters and now dominate a once good site. I was there due to Vidpok. You, zzaatt, and moosedogger would probably appreciate stocktwits AUPH much more. There is a good amount of fud posters but also some serious posters also that dig up much more good info. Just wanted to let you know.
Winepro1, ( aka HarryCrumb).
👍️0
Cosa Cosa 3 년 전
I think you're taking the smarter approach. I'm putting myself in a higher risk higher reward situation. Nothing a few drinks can't fix lol.
👍️0
randychub randychub 3 년 전
Hoping I don’t miss the boat but I’m waiting for the FDA letter
👍️0
Cosa Cosa 3 년 전
Market cap below $1B. 2 year low. I bought more at $9.64 averaging down. Back in 2019 it went from high of $26 down to $4.50. I wonder if that is going to this year. Bio's keep getting hammered.
👍️0
DewDiligence DewDiligence 3 년 전
There is still time for the FDA to deliberate about the problem in question between now the 5/6/22 PDUFA date.
👍️0
randychub randychub 3 년 전
“The FDA noted that the letter does not reflect a final decision on the pending sNDA and that the application is still under review”

Any thoughts on why the FDA has not yet given a final decision?
👍️0